- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05327725
Fatigue Reduction Diet in Lymphoma Survivors
August 30, 2024 updated by: Tonya Orchard, Ohio State University Comprehensive Cancer Center
Fatigue Reduction Diet in Survivors of Diffuse Large B-Cell Lymphomas; a Preliminary Study
The purpose of this small preliminary study is to gather preliminary data to support a large randomized controlled trial of a fatigue reduction diet intervention among diffuse-large B-cell lymphoma (DLBCL) survivors.
This study will provide nutritional counseling to 10 adult patients (18 years or older) with DLBCL who have completed their upfront chemotherapy treatment and remained in remission for 2 years prior to enrollment.
The study will employ individualized dietary counseling, provided by a registered dietitian (RD), by phone or video teleconferencing in 8 sessions over 3 months.
Dietary intake and fatigue will be assessed at baseline and 3 months.
The objective of the study is to determine feasibility of the intervention and adherence to the fatigue reduction diet.
Data obtained from this preliminary study would be used to support a well-powered future randomized trial of FRD vs regular diet in survivors of DLBCL.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Fatigue is highly prevalent in survivors of diffuse-large B-cell lymphoma (DLBCL).
Fatigue has been linked to chronic inflammation, and diets high in antioxidant nutrients (diet rich in fruit, vegetables, whole grains, and omega-3 fatty acid-rich foods) have been associated with lesser prevalence and severity of fatigue.
Studies are needed, however, to test if antioxidant-rich diets could improve fatigue in this patient population.
This fatigue-reducing diet (FRD) was shown to improve fatigue and sleep in breast cancer survivors compared to regular diet.
This FRD diet aligns with the standard of care dietary recommendations for cancer survivors promoted by the American Cancer Society (ACS) .
The purpose of this small preliminary study is to gather preliminary data to support a large randomized controlled trial.
This study will provide nutritional counseling to 10 adult patients (18 years or older) with DLBCL who have completed their upfront chemotherapy treatment and remained in remission for 2 years prior to enrollment.
The study will employ individualized dietary counseling, provided by a registered dietitian (RD), by phone or video teleconferencing.
Phone counseling will be weekly for the first month, and then biweekly for the next two months, for a total of 8 phone sessions.
Counseling sessions take ~15-30 minutes.
Dietary intake will be assessed using an electronic food frequency questionnaire at baseline and 3 months.
Fatigue will be assessed using an online survey at baseline and 3 months.
The purpose of the study to ascertain the percentage of patients who are able to complete all the study questionnaires and visits and adhere to the fatigue reduction diet.
Data obtained from this preliminary study would be used to support a well-powered future randomized trial of FRD vs regular diet in survivors of DLBCL.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adult patients (18+) with Diffuse large B-cell lymphoma (DLBCL) who have completed their upfront chemoimmunotherapy, and remained in remission for 2 years prior to enrollment
Exclusion Criteria:
- Unable to provide consent or speak English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Fatigue Reduction Diet Intervention
Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol via 8 remote phone or video telehealth sessions with a registered dietitian over 3 months.
|
Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of intervention
Time Frame: 3 months
|
Determine feasibility of recruiting, enrolling and retaining participants in the study, represented as percentage of patients who completed the study.
|
3 months
|
|
Adherence to fatigue reduction diet
Time Frame: 3 months
|
Determine percentage of patients who adhered to the fatigue reduction diet protocol
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Tonya Orchard, PhD, Ohio State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2021
Primary Completion (Actual)
September 24, 2021
Study Completion (Actual)
September 24, 2021
Study Registration Dates
First Submitted
April 7, 2022
First Submitted That Met QC Criteria
April 7, 2022
First Posted (Actual)
April 14, 2022
Study Record Updates
Last Update Posted (Actual)
September 4, 2024
Last Update Submitted That Met QC Criteria
August 30, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-20182
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Large B-Cell, Diffuse
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)Not yet recruitingDiffuse Large B Cell Lymphoma Refractory | Large B Cell Lymphoma | Diffuse Large B Cell Lymphoma Relapsed | Non Hodgkin Lymphoma (NHL) | Diffuse Large B Cell Lymphoma (DLBCL)United States
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
National Cancer Institute (NCI)Active, not recruitingLymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditionsUnited States
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Fatigue Reduction Diet
-
University of Michigan Rogel Cancer CenterAmerican Institute for Cancer ResearchRecruiting
-
Indiana UniversityNational Cancer Institute (NCI); Walther Cancer InstituteCompleted
-
Research on Healthcare Performance Lab U1290Enrolling by invitationHealth Behavior | Health-Related BehaviorFrance
-
Research on Healthcare Performance Lab U1290Enrolling by invitationHealth Behavior | Health-Related BehaviorFrance
-
Virginia Polytechnic Institute and State UniversityCompleted
-
Rush University Medical CenterTerminatedInflammation | Inflammatory Response | Menopause | Aging | Telomere Shortening | Menopause Syndrome | Stress OxidativeUnited States
-
University of TorontoCompletedProtein/Amino Acid Metabolism | Indicator Amino Acid Oxidation MethodCanada
-
Shahid Beheshti University of Medical SciencesCompletedObesityIran, Islamic Republic of
-
Istinye UniversityRecruitingMental Fatigue | Muscular FatigueTurkey (Türkiye)
-
Riphah International UniversityRecruitingFatigue | Cognitive LoadPakistan